Pfizer targets VEGF bispecific white space
The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
SGO 2026 – GSK bucks the B7-H4 trend
The group impresses in ovarian and endometrial cancers.
Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Genmab takes its Profound buy into endometrial
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
Acrivon CHKs itself
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
